Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given a consensus recommendation of “Hold” by the seventeen analysts that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $29.3667.

A number of brokerages have recently issued reports on HIMS. TD Cowen cut their price target on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a report on Friday, March 27th. Zacks Research downgraded shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, June 8th. Morgan Stanley cut their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Barclays raised their price target on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Leerink Partners raised their price target on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a report on Monday, March 16th.

Insider Buying and Selling at Hims & Hers Health

In other news, Director David B. Wells purchased 48,400 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was acquired at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the acquisition, the director directly owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. This represents a 27.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 9,463 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the sale, the insider owned 299,368 shares of the company’s stock, valued at $8,981,040. This represents a 3.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 122,050 shares of company stock worth $3,409,540. Insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Capital World Investors increased its holdings in Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after purchasing an additional 223,892 shares during the last quarter. Farallon Capital Management LLC increased its holdings in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the last quarter. State Street Corp increased its holdings in Hims & Hers Health by 1.8% in the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after purchasing an additional 132,311 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Hims & Hers Health by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after purchasing an additional 608,950 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Barclays raised its price target on Hims & Hers and maintained a bullish stance, reinforcing optimism around accelerating growth and margin improvement tied to the Novo Nordisk partnership. Hims & Hers Stock Jumps After Barclays Raises Price Target
• Positive Sentiment: Analysts and commentators see the company as a potential beneficiary of the peptide/GLP-1 market and an upcoming FDA review, which may provide a new catalyst for future growth. HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
• Positive Sentiment: Bullish coverage argues that international expansion and the renewed partnership with Novo Nordisk support Hims & Hers’ long-term revenue and EBITDA targets. Hims & Hers: The Bull Case Remains Strong
• Neutral Sentiment: Insider selling by Irene Becklund and COO Michael Chi was disclosed, but both transactions were tied to pre-arranged 10b5-1 plans and equity-award tax withholding, which makes the signal less concerning for investors. SEC filing for Michael Chi sale
• Negative Sentiment: Recent commentary still points to weak prior-quarter fundamentals, including modest revenue growth, declining margins, and a net loss, reminding investors that execution risk remains. Hims & Hers: The Bull Case Remains Strong

Hims & Hers Health Stock Up 11.1%

HIMS stock opened at $35.44 on Friday. The company has a market cap of $8.20 billion, a price-to-earnings ratio of -393.79, a PEG ratio of 45.59 and a beta of 2.37. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $70.43. The firm has a 50-day moving average of $26.42 and a two-hundred day moving average of $26.58.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.20 EPS. As a group, analysts forecast that Hims & Hers Health will post 0.05 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.